Effexor (Major Depressive Disorder) Market Research & Emerging Trends Report to 2023

Effexor (Major Depressive Disorder) Market Size, Share, Global Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Effexor (venlafaxine) is an antidepressant that belongs to the SNRI class. It was developed and

launched by Wyeth, which was later fully acquired by Pfizer. Effexor first became available in

the US and 5EU in 1994, and its extended release formulation (Effexor XR) was introduced into

the US and 5EU markets in 1998.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

Browse full report on: http://www.radiantinsights.com/research/effexor-major-depressivedisorder-forecast-and-market-analysis-to-2023

- Detailed information on Effexor including product description, safety and efficacy profiles as

well as a SWOT analysis.

- Sales forecast for Effexor for the top seven countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Major

depressive disorder

-...